Catalog No.
EVV22001
Expression system
Mammalian Cells
Species
Epstein-Barr virus (strain GD1) (HHV-4) (Human herpesvirus 4)
Protein length
Ala22-Gly735
Predicted molecular weight
82.68 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
R4R670
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Envelope glycoprotein B, gB, BALF4, gB, EBVaGC1_061
A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection., PMID:40338258
A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo., PMID:40272901
Broad-spectrum antiviral activity of Ganoderma microsporum immunomodulatory protein: Targeting glycoprotein gB to inhibit EBV and HSV-1 infections via viral fusion blockage., PMID:40101816
Integrated Proteomics and Machine Learning Approach Reveals PYCR1 as a Novel Biomarker to Predict Prognosis of Sinonasal Squamous Cell Carcinoma., PMID:39768999
An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virus., PMID:39499444
Structures of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus virions reveal species-specific tegument and envelope features., PMID:39470208
CD4 T cells restricted to DRB1*15:01 recognize two Epstein-Barr virus glycoproteins capable of intracellular antigen presentation., PMID:39432795
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice., PMID:39346922
Structures of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus virions reveal species-specific tegument and envelope features., PMID:39026862
GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection., PMID:39020055
Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern Italy., PMID:38921797
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection., PMID:38906867
Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases., PMID:38587217
Molecular Detection and Genetic Diversity of Cytomegaloviruses and Lymphocryptoviruses in Free-Roaming and Captive African Green Monkeys (Chlorocebus sabaeus)., PMID:38542246
Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice., PMID:38201224
mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice., PMID:37890462
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV., PMID:37848029
The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review., PMID:37334371
Urgency and necessity of Epstein-Barr virus prophylactic vaccines., PMID:36494369
Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion., PMID:35917353
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells., PMID:35711430
Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia., PMID:35572604
Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective., PMID:35493498
Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses., PMID:35404082
Potential entry receptors for human γ-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections., PMID:34800753
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases., PMID:34691042
Evolution and long-term outcomes of combined immunodeficiency due to CARMIL2 deficiency., PMID:34287962
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer., PMID:34154654
Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge., PMID:33808755
T cell epitope screening of Epstein-Barr virus fusion protein gB., PMID:33658348
Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients., PMID:33493797
Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma., PMID:33268566
The structural basis of herpesvirus entry., PMID:33087881
Immune-mediated genesis of multiple sclerosis., PMID:32743522
A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits., PMID:32268575
Eph receptors: the bridge linking host and virus., PMID:31893311
Predictors of Epstein-Barr virus serostatus in young people in England., PMID:31779585
Gammaherpesvirus entry and fusion: A tale how two human pathogenic viruses enter their host cells., PMID:31439152
Epstein-Barr virus infection with acute acalculous cholecystitis in previously healthy children., PMID:31243873
Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology., PMID:30727744
Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein-Barr virus (EBV)., PMID:30679646
Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation., PMID:30052682
Acidic pH Mediates Changes in Antigenic and Oligomeric Conformation of Herpes Simplex Virus gB and Is a Determinant of Cell-Specific Entry., PMID:29925660
An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus., PMID:29669253
Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry., PMID:29292383
Epstein-Barr Virus Fusion with Epithelial Cells Triggered by gB Is Restricted by a gL Glycosylation Site., PMID:28956769
Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies., PMID:28939750
The COMPLEXity in herpesvirus entry., PMID:28538165
The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment., PMID:27935841
Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice., PMID:27926486
For research use only. Not for human or drug use.
